Identification of counterfeit medicines for erectile dysfunction by validated RP-HPLC method
Abstract
Purpose: The aim of the study was to develop a specific, sensitive, simple, and rapid RP-HPLC method with UV detection for identification of counterfeit medicines for erectile dysfunction: containing vardenafil, sildenafil, and tadalafil. Material and Methods: HPLC analysis was performed using a Schimadzu LC-2010 chromatographic system (Schimadzu, Kyoto, Japan) consisting of a LC-20AT Prominence liquid chromatograph pump with DGU-20A5 Prominence degasser, a SPD-M20A Prominence Diode Array Detector, and a SIL-20 AC Prominence auto sampler. Data analyses were done using Class VP 7.3 Software. The elution was carried out on a column Chromolith® Performance RP-18e (50 x 4.6 mm i.d., monolithic rod), with a mobile phase consisted of acetonitrile and 0.02 mol L-1 phosphate buffer (pH = 2.8) in a ratio of 29:71, (V/V), at flow rate of 0.6 mL min-1, at controlled column temperature (40°C) and autosamler temperature at 4oC. Detection of vardenafil, sildenafil, and tadalafil was carried out with DAD detector at a wavelength of 285 nm. The injection volume was 20 μl. The samples included medicines for erectile dysfunction (sildenafil 50 mg tablets, tadalafil 20 mg tablets, vardenafil 10 mg tablets) and were submitted by the state regulatory authority, Bureau of the medicines. Results: The method was fully validated according to the ICH (International Conference on Harmonization) guidelines by the determination of linearity, precision, accuracy, limit of detection (LOD) and limit of…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.